|
79
|
268
|
4ftqA |
Crystal structure of the chk1 |
|
82
|
278
|
4fsqA |
Crystal structure of the chk1 |
|
270
|
945
|
4fjyA |
Crystal structure of pi3k-gamma in complex with quinoline-indoline inhibitor 24f |
|
85
|
281
|
4fzaB |
Crystal structure of mst4-mo25 complex |
|
79
|
278
|
4ft3A |
Crystal structure of the chk1 |
|
81
|
269
|
4ftoA |
Crystal structure of the chk1 |
|
81
|
278
|
4fszA |
Crystal structure of the chk1 |
|
262
|
948
|
4fhkA |
Crystal structure of pi3k-gamma in complex with imidazopyridazine 19e |
|
90
|
316
|
3r1nA |
Mk3 kinase bound to compound 5b |
|
117
|
333
|
4fbxA |
Complex structure of human protein kinase ck2 catalytic subunit crystallized in the presence of a bisubstrate inhibitor |
|
94
|
292
|
4fijA |
Catalytic domain of human pak4 |
|
72
|
299
|
3r2bA |
Mk2 kinase bound to compound 5b |
|
66
|
264
|
3r22A |
Design, synthesis, and biological evaluation of pyrazolopyridine-sulfonamides as potent multiple-mitotic kinase (mmk) inhibitors (part i) |
|
67
|
271
|
4fk3A |
B-raf kinase v600e oncogenic mutant in complex with plx3203 |
|
81
|
275
|
4fc0A |
Crystal structure of human kinase domain of b-raf with a dfg-out inhibitor |
|
109
|
327
|
3r0tA |
Crystal structure of human protein kinase ck2 alpha subunit in complex with the inhibitor cx-5279 |
|
80
|
271
|
3r02A |
The discovery of novel benzofuran-2-carboxylic acids as potent pim-1 inhibitors |
|
262
|
946
|
3qk0A |
Crystal structure of pi3k-gamma in complex with benzothiazole 82 |
|
74
|
263
|
3r21A |
Design, synthesis, and biological evaluation of pyrazolopyridine-sulfonamides as potent multiple-mitotic kinase (mmk) inhibitors (part i) |
|
93
|
294
|
4fifA |
Catalytic domain of human pak4 with rpkplvdp peptide |
|
85
|
377
|
4fieA |
Full-length human pak4 |
|
263
|
945
|
3qaqA |
Crystal structure of pi3k-gamma in complex with triazine-benzimidazole 1 |
|
79
|
274
|
3r01A |
The discovery of novel benzofuran-2-carboxylic acids as potent pim-1 inhibitors |
|
261
|
943
|
3qjzA |
Crystal structure of pi3k-gamma in complex with benzothiazole 1 |
|
93
|
292
|
4fihA |
Catalytic domain of human pak4 with qkftglprqw peptide |
|
73
|
300
|
3r2yA |
Mk2 kinase bound to compound 1 |
|
81
|
271
|
3r04A |
The discovery of novel benzofuran-2-carboxylic acids as potent pim-1 inhibitors |
|
96
|
292
|
4fiiA |
Catalytic domain of human pak4 with rpkplvdp peptide |
|
79
|
274
|
3r00A |
The discovery of novel benzofuran-2-carboxylic acids as potent pim-1 inhibitors |
|
91
|
293
|
4figA |
Catalytic domain of human pak4 |
|
129
|
371
|
4fi1A |
Crystal structure of scck2 alpha in complex with atp |
|
279
|
946
|
3qarA |
Crystal structure of pi3k-gamma in complex with triazine-benzimidazole 32 |
|
73
|
300
|
3r30A |
Mk2 kinase bound to compound 2 |
|
82
|
274
|
3qf9A |
Crystal structure of human proto-oncogene serine threonine kinase (pim1) in complex with a consensus peptide and a furan-thiazolidinedione ligand |
|
89
|
286
|
3qd0A |
Phosphoinositide-dependent kinase-1 (pdk1) kinase domain with (2r,5s)-1-[2-amino-6-(3-amino-1h-indazol-6-yl)-4-pyrimidinyl]-6-methyl-n-phenyl-3-piperidinecarboxamide |
|
265
|
950
|
3ps6A |
Quinazolines with intra-molecular hydrogen bonding scaffold (imhbs) as pi3k/mtor dual inhibitors. |
|
81
|
286
|
3qcxA |
Phosphoinositide-dependent kinase-1 (pdk1) kinase domain with 6-{2-amino-6-[(3r)-3-methyl-4-morpholinyl]-4-pyrimidinyl}-1h-indazol-3-amine |
|
0
|
10
|
3qkkC |
Spirochromane akt inhibitors |
|
263
|
950
|
3przA |
Quinazolines with intra-molecular hydrogen bonding scaffold (imhbs) as pi3k/mtor dual inhibitors. |
|
78
|
332
|
3qd2B |
Crystal structure of mouse perk kinase domain |
|
24
|
101
|
3qp3A |
Crystal structure of titin domain m4, tetragonal form |
|
103
|
414
|
3qfvA |
Mrck beta in complex with tpca-1 |
|
88
|
286
|
3qcyA |
Phosphoinositide-dependent kinase-1 (pdk1) kinase domain with 4-[2-amino-6-(3-amino-1h-indazol-6-yl)-4-pyrimidinyl]-n-phenyl-2-morpholinecarboxamide |
|
99
|
335
|
3qkkA |
Spirochromane akt inhibitors |
|
97
|
335
|
3qklA |
Spirochromane akt inhibitors |
|
81
|
286
|
3qcsA |
Phosphoinositide-dependent kinase-1 (pdk1) kinase domain with 6-[2-amino-6-(4-morpholinyl)-4-pyrimidinyl]-1h-indazol-3-amine |
|
98
|
335
|
3qkmA |
Spirocyclic sulfonamides as akt inhibitors |
|
267
|
950
|
3preA |
Quinazolines with intra-molecular hydrogen bonding scaffold (imhbs) as pi3k/mtor dual inhibitors. |
|
85
|
288
|
3qd4A |
Phosphoinositide-dependent kinase-1 (pdk1) kinase domain with 1,1-dimethylethyl{(3r,5r)-1-[2-amino-6-(3-amino-1h-indazol-6-yl)-4-pyrimidinyl]-5-methyl-3-piperidinyl}carbamate |
|
81
|
286
|
3qcqA |
Phosphoinositide-dependent kinase-1 (pdk1) kinase domain with 6-(3-amino-1h-indazol-6-yl)-n4-ethyl-2,4-pyrimidinediamine |
